CD271 antibody-functionalized microspheres capable of selective recruitment of reparative endogenous stem cells for in situ bone regeneration.

Biomaterials

Department of Articular Orthopaedics, Orthopaedic Institute, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu, China; Department of Orthopaedic Surgery, The First Affiliated Hospital, Orthopedic Institute, Soochow University, Suzhou, Jiangsu, China; China Orthopaedic Regenerative Medicine Group (CORMed), Hangzhou, Zhejiang, China. Electronic address:

Published: January 2022

In the strategy of in situ bone regeneration, it used to be difficult to specifically recruit bone marrow mesenchymal stem cells (BM-MSCs) by a single marker. Recently, CD271 has been considered to be one of the most specific markers to isolate BM-MSCs; however, the effectiveness of CD271 antibodies in recruiting BM-MSCs has not been explored yet. In this study, we developed novel CD271 antibody-functionalized chitosan (CS) microspheres with the aid of polydopamine (PDA) coating to recruit endogenous BM-MSCs for in situ bone regeneration. The CS microspheres were sequentially modified with PDA and CD271 antibody through dopamine self-polymerization and bioconjugation, respectively. In vitro studies showed that the CD271 antibody-functionalized microspheres selectively captured significantly more BM-MSCs from a fluorescently labeled heterotypic cell population than non-functionalized controls. In addition, the PDA coating was critical for supporting stable adhesion and proliferation of the captured BM-MSCs. Effective early recruitment of CD271 stem cells by the functionalized microspheres at bone defect site of SD rat was observed by the CD271/DAPI immunofluorescence staining, which led to significantly enhanced new bone formation in rat femoral condyle defect over long term. Together, findings from this study have demonstrated, for the first time, that the CD271 antibody-functionalized CS microspheres are promising for in situ bone regeneration.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2021.121243DOI Listing

Publication Analysis

Top Keywords

cd271 antibody-functionalized
16
situ bone
16
bone regeneration
16
antibody-functionalized microspheres
12
stem cells
12
cd271
8
pda coating
8
captured bm-mscs
8
bone
7
microspheres
6

Similar Publications

CD271 antibody-functionalized microspheres capable of selective recruitment of reparative endogenous stem cells for in situ bone regeneration.

Biomaterials

January 2022

Department of Articular Orthopaedics, Orthopaedic Institute, The Third Affiliated Hospital, Soochow University, Changzhou, Jiangsu, China; Department of Orthopaedic Surgery, The First Affiliated Hospital, Orthopedic Institute, Soochow University, Suzhou, Jiangsu, China; China Orthopaedic Regenerative Medicine Group (CORMed), Hangzhou, Zhejiang, China. Electronic address:

In the strategy of in situ bone regeneration, it used to be difficult to specifically recruit bone marrow mesenchymal stem cells (BM-MSCs) by a single marker. Recently, CD271 has been considered to be one of the most specific markers to isolate BM-MSCs; however, the effectiveness of CD271 antibodies in recruiting BM-MSCs has not been explored yet. In this study, we developed novel CD271 antibody-functionalized chitosan (CS) microspheres with the aid of polydopamine (PDA) coating to recruit endogenous BM-MSCs for in situ bone regeneration.

View Article and Find Full Text PDF

Cancer stem cells (CSCs) are considered to maintain the vitality of tumor cell populations through self-renewal and infinite proliferation, but their accessibility is still under investigation. In addition, CSCs are more resistant to chemotherapy and radiotherapy compared with common tumor cells. This study aimed to develop a kind of novel and feasible nanomaterial for targeted photothermal ablation of osteosarcoma stem cells, which could be a promising anticancer strategy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!